Guideline Recommendations and Implementation Gaps for SGLT2 Inhibitors

This episode, "Guideline Recommendations and Implementation Gaps for SGLT2 Inhibitors," features Dr. Vaduganathan reviewing how cardiology, nephrology, and endocrinology guidelines have converged on SGLT2 inhibitors.

Dr. Vaduganathan surveys how guidelines have converged on SGLT2 inhibitors as first-line therapy. He explains that heart failure clinical practice guidelines give the class a Class 1 recommendation in many global guidelines, regardless of a patient's ejection fraction. Leading kidney disease guidelines take a similar stance, recommending SGLT2 inhibitors as early, upfront therapy for chronic kidney disease irrespective of whether a patient also has diabetes. Endocrine societies, including the American Diabetes Association, strongly recommend the class for patients with diabetes who carry cardiovascular or kidney risk. Dr. Vaduganathan highlights this year's joint guideline release from four US societies covering cardio-kidney-metabolic, or CKM, disease, which positions SGLT2 inhibitors as a foundational pillar of care across broad CKM populations, both to mitigate complications early and to treat complications once present.

Despite that guideline consensus, Dr. Vaduganathan is candid that implementation has lagged at the clinician level, and he walks through why. Education gaps mean it takes time for awareness of a therapy class to spread through the broader clinical community. Access barriers, including early insurance hurdles and cost, can delay uptake even when clinicians are convinced. Clinical inertia plays a role too: patients who are already doing reasonably well with diabetes, heart failure, or kidney disease are often not flagged as candidates for further optimization, since they present as stable during routine ambulatory visits. Dr. Vaduganathan explains that clinicians may see little immediate reason to change a regimen that appears to be working, even when added therapy could meaningfully change long-term outcomes. He closes by noting that many of these barriers are now starting to be addressed as SGLT2 inhibitors become more familiar and more accessible to both clinicians and patients.

Our next episode, "SGLT2 Inhibitor Cardiovascular Outcomes Trials: What the Data Show," turns to the clinical trial evidence itself, walking through the major cardiovascular outcomes trials behind the class.Welcome back to another AJMC Insights series. In "SGLT2 Inhibitors' Growing Role Across Cardio-Kidney-Metabolic Care," Dr. Vaduganathan opens the series by tracing the rapid expansion of SGLT2 inhibitors across cardiovascular, kidney, and metabolic disease care.